Vivos Therapeutics (VVOS) Prices 4M Share Follow-On Offering at $6/Sh

May 7, 2021 5:58 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the pricing of its underwritten follow-on public offering of 4,000,000 shares of its common stock at a public offering price of $6.00 per share.

The aggregate gross proceeds to Vivos from the public offering are expected to be $24 million prior to deducting underwriting discounts, commissions, and other estimated offering expenses. Vivos has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of common stock to cover over-allotments, if any.

Roth Capital Partners is acting as sole book-running manager and representative of the underwriters for the offering. National Securities Corporation and Craig-Hallum Capital Group are acting as co-managers of the offering.

The Securities and Exchange Commission (“SEC”) declared effective registration statements on Form S-1 relating to these securities on May 6, 2021.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Equity Offerings

Related Entities

Roth Capital, S1